BACKGROUND: Exposure to gadolinium-based contrast agents (GBCA) in patients with chronic kidney disease (CKD) has been associated with the development of a potentially fatal disorder, nephrogenic systemic fibrosis (NSF). Although contrast-enhanced computed tomography (CT) is an alternative to magnetic resonance imaging (MRI), it carries the risk of radiation exposure and further reduction of residual renal function. Therefore we sought to assess the feasibility of ferumoxytol as an alternative to GBCA for contrast-enhanced MR angiography (MRA) in a pediatric cohort with CKD. Ferumoxytol is a parenteral iron supplement that contains ultrasmall superparamagnetic iron oxide (USPIO) and is a potent relaxivity agent for MRI. METHODS: We describe the MRI findings in ten pediatric patients who needed detailed vascular mapping. Ferumoxytol (4 mg/kg) was administered intravenously for contrast-enhanced MRA. The patients tolerated the procedure without complications. RESULTS: Resulting studies were highly diagnostic and were pivotal in guiding patient management. The images were notable for clear delineation of multiple vascular occlusions. CONCLUSIONS: Given the concerns associated with the use of GBCAs in renal failure, ferumoxytol is an excellent alternative contrast agent in pediatric end stage renal disease (ESRD) patients. Future studies are needed in order to further evaluate safety and efficacy of ferumoxytol in this patient population.
BACKGROUND: Exposure to gadolinium-based contrast agents (GBCA) in patients with chronic kidney disease (CKD) has been associated with the development of a potentially fatal disorder, nephrogenic systemic fibrosis (NSF). Although contrast-enhanced computed tomography (CT) is an alternative to magnetic resonance imaging (MRI), it carries the risk of radiation exposure and further reduction of residual renal function. Therefore we sought to assess the feasibility of ferumoxytol as an alternative to GBCA for contrast-enhanced MR angiography (MRA) in a pediatric cohort with CKD. Ferumoxytol is a parenteral iron supplement that contains ultrasmall superparamagnetic iron oxide (USPIO) and is a potent relaxivity agent for MRI. METHODS: We describe the MRI findings in ten pediatric patients who needed detailed vascular mapping. Ferumoxytol (4 mg/kg) was administered intravenously for contrast-enhanced MRA. The patients tolerated the procedure without complications. RESULTS: Resulting studies were highly diagnostic and were pivotal in guiding patient management. The images were notable for clear delineation of multiple vascular occlusions. CONCLUSIONS: Given the concerns associated with the use of GBCAs in renal failure, ferumoxytol is an excellent alternative contrast agent in pediatric end stage renal disease (ESRD) patients. Future studies are needed in order to further evaluate safety and efficacy of ferumoxytol in this patient population.
Authors: Jason S Weinstein; Csanad G Varallyay; Edit Dosa; Seymur Gahramanov; Bronwyn Hamilton; William D Rooney; Leslie L Muldoon; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2009-09-16 Impact factor: 6.200
Authors: Seymur Gahramanov; Ahmed M Raslan; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Csanad G Varallyay; Jeffrey M Njus; Marianne Haluska; Edward A Neuwelt Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-13 Impact factor: 7.038
Authors: Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira Journal: J Am Soc Nephrol Date: 2008-06-04 Impact factor: 10.121
Authors: Steven Y Huang; Charles Y Kim; Michael J Miller; Rajan T Gupta; Mark L Lessne; Jeffrey J Horvath; Daniel T Boll; Paul D Evans; Nicholas T Befera; Pranay Krishnan; Johanna L Chan; Elmar M Merkle Journal: AJR Am J Roentgenol Date: 2013-07 Impact factor: 3.959
Authors: Csanad G Varallyay; Eric Nesbit; Andrea Horvath; Peter Varallyay; Rongwei Fu; Seymur Gahramanov; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt Journal: J Magn Reson Imaging Date: 2018-01-04 Impact factor: 4.813
Authors: Michael D Hope; Thomas A Hope; Chengcheng Zhu; Farshid Faraji; Henrik Haraldsson; Karen G Ordovas; David Saloner Journal: AJR Am J Roentgenol Date: 2015-06-23 Impact factor: 3.959
Authors: C G Varallyay; G B Toth; R Fu; J P Netto; J Firkins; P Ambady; E A Neuwelt Journal: AJNR Am J Neuroradiol Date: 2017-05-11 Impact factor: 3.825
Authors: Srinivasan Mukundan; Michael L Steigner; Li-Li Hsiao; Sayeed K Malek; Stefan G Tullius; Matthew S Chin; Andrew M Siedlecki Journal: Am J Kidney Dis Date: 2016-01-16 Impact factor: 8.860
Authors: Shreyas S Vasanawala; Kim-Lien Nguyen; Michael D Hope; Mellena D Bridges; Thomas A Hope; Scott B Reeder; Mustafa R Bashir Journal: Magn Reson Med Date: 2016-02-18 Impact factor: 4.668
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612